Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non-internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early-stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics.</p></section>

Bibliometric analysis of antibody-drug conjugates

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis

Antibody-drug Conjugates: Design and Clinical Progress

Development of antibody-drug conjugates in cancer: Overview and prospects

ADCdb: the Database of Antibody-Drug Conjugates

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

[Bioanalysis in the development of antibody-drug conjugates]

Antibody-drug conjugates: Principles and opportunities

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Bioanalytical assays for pharmacokinetic and biodistribution study of Antibody-Drug Conjugates

Development of antibody used by antibody-drug conjugates

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Antibody-drug Conjugates and Their Application in the Treatment of Hematological Malignancies

Research progress on novel antibody drug conjugates in cancer therapy

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Antibody drug conjugates in the clinic

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Targeting cancer with antibody-drug conjugates: Promises and challenges